Enlightmen Biotech Co., Ltd.
Update：2026/11/11
Industries
Main Industry
Biotechnology
Main Product/Service
The Mol Prospector Intelligent Preclinical Drug Discovery Platform is an AI-driven drug discovery platform specifically designed for early-stage small molecule drug R&D. Combining advanced AI algorithms with the deep expertise of the R&D team at Enlightmen Biotech Co., Ltd., the platform offers AI-driven drug discovery services, licensing of early-stage AI drug candidates, and co-development solutions. It is ideal for academic and research institutions, biotech startups, and pharmaceutical companies.
The platform can design high-potential inhibitors within 16 days, complete chemical synthesis in 2 to 3 days, and deliver in vitro-validated active lead compounds in up to 5 months. Its ADMET tool can complete toxicity predictions within minutes, effectively reducing the failure rate of animal testing.
The platform features three major competitive advantages: high predictive accuracy even with limited data, a compound synthesizability rate of up to 80% that saves up to 90% in synthesis costs, and a cell-based efficacy hit rate of 50%. These advantages make Mol Prospector a revolutionary tool for the rapid design of patentable small molecule drugs with high therapeutic potential.
The platform can design high-potential inhibitors within 16 days, complete chemical synthesis in 2 to 3 days, and deliver in vitro-validated active lead compounds in up to 5 months. Its ADMET tool can complete toxicity predictions within minutes, effectively reducing the failure rate of animal testing.
The platform features three major competitive advantages: high predictive accuracy even with limited data, a compound synthesizability rate of up to 80% that saves up to 90% in synthesis costs, and a cell-based efficacy hit rate of 50%. These advantages make Mol Prospector a revolutionary tool for the rapid design of patentable small molecule drugs with high therapeutic potential.
The content above was translated by Ai
Founded Year
2024
Unified Business No.
00068270
Status
Active
Number of Employees
0
Total Paid-in
Capital
37,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Enlightmen Biotech Co., Ltd. was co-founded by Dean Shiow-Lin Pan of the College of Medicine at Taipei Medical University and Professor Kai-Cheng Hsu, and has independently developed the AI novel drug design platform "Mol Prospector." This intelligent preclinical novel drug development platform utilizes artificial intelligence technology to significantly shorten the timeline and reduce the cost of novel drug development, and is expected to bring breakthrough therapeutic solutions for major diseases such as cancer and neurodegenerative diseases.
The content above was translated by Ai
